# Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

> **NCT00574600** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 48 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** SAAVI DNA-C2 vaccine
- **BIOLOGICAL:** SAAVI MVA-C vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00574600
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-10
- **Final completion:** 2013-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574600, "Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT00574600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*